Pembrolizumab 200 mg IV infusion
ECT2304029302
Phase 2 mab active
Quick answer
Pembrolizumab 200 mg IV infusion for Stage IIIB(N2) Non-small Cell Lung Cancer is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Stage IIIB(N2) Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- active